S&P 500   2,637.98 (-99.12%)
DOW   22,453.92 (+0.57%)
QQQ   194.23 (+1.14%)
AAPL   260.06 (+2.06%)
FB   170.17 (+2.54%)
MSFT   162.73 (+1.56%)
GOOGL   1,171.61 (+2.21%)
AMZN   1,978.99 (+0.77%)
CGC   15.03 (+3.94%)
NVDA   269.89 (+1.62%)
BABA   196.50 (+2.73%)
MU   44.62 (+0.22%)
GE   8.02 (+1.65%)
TSLA   533.79 (+6.31%)
AMD   47.90 (+0.08%)
ACB   0.95 (+6.76%)
F   5.11 (+1.59%)
NFLX   379.69 (+2.35%)
BAC   22.34 (+1.36%)
GILD   75.38 (-0.72%)
DIS   102.16 (+2.36%)
S&P 500   2,637.98 (-99.12%)
DOW   22,453.92 (+0.57%)
QQQ   194.23 (+1.14%)
AAPL   260.06 (+2.06%)
FB   170.17 (+2.54%)
MSFT   162.73 (+1.56%)
GOOGL   1,171.61 (+2.21%)
AMZN   1,978.99 (+0.77%)
CGC   15.03 (+3.94%)
NVDA   269.89 (+1.62%)
BABA   196.50 (+2.73%)
MU   44.62 (+0.22%)
GE   8.02 (+1.65%)
TSLA   533.79 (+6.31%)
AMD   47.90 (+0.08%)
ACB   0.95 (+6.76%)
F   5.11 (+1.59%)
NFLX   379.69 (+2.35%)
BAC   22.34 (+1.36%)
GILD   75.38 (-0.72%)
DIS   102.16 (+2.36%)
S&P 500   2,637.98 (-99.12%)
DOW   22,453.92 (+0.57%)
QQQ   194.23 (+1.14%)
AAPL   260.06 (+2.06%)
FB   170.17 (+2.54%)
MSFT   162.73 (+1.56%)
GOOGL   1,171.61 (+2.21%)
AMZN   1,978.99 (+0.77%)
CGC   15.03 (+3.94%)
NVDA   269.89 (+1.62%)
BABA   196.50 (+2.73%)
MU   44.62 (+0.22%)
GE   8.02 (+1.65%)
TSLA   533.79 (+6.31%)
AMD   47.90 (+0.08%)
ACB   0.95 (+6.76%)
F   5.11 (+1.59%)
NFLX   379.69 (+2.35%)
BAC   22.34 (+1.36%)
GILD   75.38 (-0.72%)
DIS   102.16 (+2.36%)
S&P 500   2,637.98 (-99.12%)
DOW   22,453.92 (+0.57%)
QQQ   194.23 (+1.14%)
AAPL   260.06 (+2.06%)
FB   170.17 (+2.54%)
MSFT   162.73 (+1.56%)
GOOGL   1,171.61 (+2.21%)
AMZN   1,978.99 (+0.77%)
CGC   15.03 (+3.94%)
NVDA   269.89 (+1.62%)
BABA   196.50 (+2.73%)
MU   44.62 (+0.22%)
GE   8.02 (+1.65%)
TSLA   533.79 (+6.31%)
AMD   47.90 (+0.08%)
ACB   0.95 (+6.76%)
F   5.11 (+1.59%)
NFLX   379.69 (+2.35%)
BAC   22.34 (+1.36%)
GILD   75.38 (-0.72%)
DIS   102.16 (+2.36%)
Log in

NYSE:DGX - Quest Diagnostics Stock Price, Forecast & News

$80.78
-2.28 (-2.75 %)
(As of 03/31/2020 11:44 AM ET)
Today's Range
$79.22
Now: $80.78
$82.98
50-Day Range
$75.14
MA: $101.85
$115.68
52-Week Range
$73.21
Now: $80.78
$118.58
Volume36,037 shs
Average Volume2.79 million shs
Market Capitalization$10.78 billion
P/E Ratio12.86
Dividend Yield2.55%
Beta0.9
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More
Quest Diagnostics logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$8.84 per share
Book Value$42.22 per share

Profitability

Net Income$858 million

Miscellaneous

Employees47,000
Market Cap$10.78 billion
Next Earnings Date4/28/2020 (Estimated)
OptionableOptionable

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.


Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

How has Quest Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DGX shares have decreased by 19.0% and is now trading at $80.78. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Quest Diagnostics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 3 sell ratings, 8 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Quest Diagnostics.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Quest Diagnostics.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) released its quarterly earnings results on Thursday, January, 30th. The medical research company reported $1.67 EPS for the quarter, topping the Zacks' consensus estimate of $1.60 by $0.07. The medical research company had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a net margin of 11.10% and a return on equity of 16.15%. The business's quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm earned $1.36 earnings per share. View Quest Diagnostics' earnings history.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Thursday, January 30th. Investors of record on Tuesday, April 7th will be paid a dividend of $0.56 per share on Tuesday, April 21st. This represents a $2.24 annualized dividend and a dividend yield of 2.77%. The ex-dividend date of this dividend is Monday, April 6th. This is a boost from Quest Diagnostics's previous quarterly dividend of $0.53. View Quest Diagnostics' dividend history.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of at least $6.60 for the period, compared to the Thomson Reuters consensus estimate of $6.73. The company issued revenue guidance of $7.80 billion to $7.90 billion, compared to the consensus revenue estimate of $7.89 billion.

What price target have analysts set for DGX?

17 analysts have issued 1-year price objectives for Quest Diagnostics' stock. Their forecasts range from $80.00 to $140.00. On average, they anticipate Quest Diagnostics' stock price to reach $107.19 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price. View analysts' price targets for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. According to Zacks Investment Research, "Quest Diagnostics reported a strong fourth quarter with both earnings and revenues beating the respective Zacks Consensus Estimate. Revenues for Diagnostic Information Services grew on strong volume growth, an easy comparable and acquisitions amid significant reimbursement pressure related to PAMA. We are upbeat about the company’s expanded network access, which helped accelerate volume growth in the quarter. The current-year outlook seems promising despite the company’s having reckoned another year of meaningful reimbursement. Quest Diagnostics has outperformed its industry over the past six months. On the flip side, the company is currently facing several PAMA-related reimbursement issues and pricing pressure. This apart, escalating costs and a tough competitive landscape are concerns." (3/16/2020)
  • 2. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)

Has Quest Diagnostics been receiving favorable news coverage?

Media headlines about DGX stock have been trending very positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Quest Diagnostics earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutQuest Diagnostics.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 5,578,200 shares, an increase of 57.1% from the February 27th total of 3,550,000 shares. Based on an average daily volume of 1,060,000 shares, the days-to-cover ratio is currently 5.3 days. Approximately 4.2% of the shares of the company are sold short. View Quest Diagnostics' Current Options Chain.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Honeywell International (HON), Johnson & Johnson (JNJ), Micron Technology (MU), AT&T (T), Aegean Marine Petroleum Network (ANW) and QUALCOMM (QCOM).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $80.78.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $10.78 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 47,000 workers across the globe. View additional information about Quest Diagnostics.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is http://www.questdiagnostics.com/.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  460 (Vote Outperform)
Underperform Votes:  871 (Vote Underperform)
Total Votes:  1,331
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: How is inflation measured?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel